Abstract: A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.
Type:
Application
Filed:
January 6, 2021
Publication date:
September 16, 2021
Applicant:
Ascendis Pharma GmbH
Inventors:
Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
Abstract: A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.
Type:
Grant
Filed:
February 5, 2013
Date of Patent:
January 19, 2016
Assignee:
Ascendis Pharma GmbH
Inventors:
Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
Abstract: A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety—such as a drug—can be released by cleaving the temporary linkage.
Type:
Grant
Filed:
June 21, 2006
Date of Patent:
March 17, 2015
Assignee:
Ascendis Pharma GmbH
Inventors:
Dirk Vetter, Harald Rau, Thomas Wegge, Ulrich Hersel
Abstract: A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier.
Abstract: The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target.
Type:
Grant
Filed:
December 14, 2010
Date of Patent:
May 28, 2013
Assignee:
Ascendis Pharma GmbH
Inventors:
Dirk Vetter, Ulrich Hersel, Harald Rau, Robert Schnepf, Thomas Wegge
© 2024 Justia
